AcelRx puts Zalviso NDA resubmission on hold; shares slammed

Shares of AcelRx Pharmaceuticals plummeted about 30% on 5 May after the FDA reiterated its earlier demand that a new clinical trial was needed before the company resubmits its new drug application (NDA) for Zalviso, a pre-programmed, non-invasive, handheld system that delivers 15mcg per dose as needed of the opioid sufentanil, allowing hospital patients to self-dose in managing their pain.

Shares of AcelRx Pharmaceuticals plummeted about 30% on 5 May after the FDA reiterated its earlier demand that a new clinical trial was needed before the company resubmits its new drug application (NDA) for Zalviso, a pre-programmed, non-invasive, handheld system that delivers 15mcg per dose as needed of the opioid sufentanil, allowing hospital patients to self-dose in managing their pain.

So AcelRx said it has put its resubmission plans on hold while it seeks input from regulatory, legal and clinical...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category